Muammer Buyukinan

Dr. Muammer Buyukinan

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Metabolic Syndrome and Related Disorders
Verified
Journal Article
Closed access
MBMuammer Buyukinan
Muammer Buyukinan
MAMuge Atar
Muge Atar
UCUmmugulsum Can
Ummugulsum Can
OPOzgur Pirgon
Ozgur Pirgon
AGAsuman Guzelant
Asuman Guzelant
IDIsa Deniz
Isa Deniz
Background and Aim: Excess visceral fat accumulation results in altered release of adipokines. The aim of this study was to examine the relationship between new adipokines (omentin-1 and vaspin), insulin resistance, and serum inflammatory markers in obese subjects with metabolic syndrome (MS). Patients and Methods: The study included a total of 121 obese children (79 females and 42 males, aged 12–17 years old). The obese subjects were divided into two groups based on the presence or absence of MS criteria (MS group and non-MS group). Serum omentin-1, vaspin, and high-sensitivity C-reactive protein (CRP) were measured in addition to the other glucose metabolism parameters. Results: MS was diagnosed in 45 obese children and 76 children did not meet the MS criteria. Serum omentin-1 (289.5 ± 51.9 ng/mL vs. 268.2 ± 60 ng/mL, P = 0.03) levels were significantly lower in the MS group compared to the non-MS group. Serum vaspin levels (1058.3 ± 118 pg/mL vs. 1178.6 ± 158 pg/mL, P = 0.02) were higher in the MS group than the non-MS group. CRP levels correlated well with both the adipokines (r = −0.236, P = 0.04 for omentin-1 and r = 0.296, P = 0.008 for vaspin), although these adipokines did not show statistically significant correlations with fasting glucose–insulin levels, homeostasis model assessment of insulin resistance, and 2 hr postload glucose level. Conclusions: Higher vaspin and lower omentin-1 levels were determined in obese MS children compared to non-MS children and these adipokines were significantly correlated with high CRP values. These data support the view that adipokines in MS children contribute to increased inflammation markers before abnormal glucose metabolism.

1 June 2019 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
IEİhsan Esen
İhsan Esen
EBElvan Bayramoğlu
Elvan Bayramoğlu
MYMelek Yıldız
Melek Yıldız
MAMurat Aydın
Murat Aydın
EKEsin Karakilic‐Ozturan
Esin Karakilic‐Ozturan
ESElif Sağsak
Elif Sağsak
Objective: To determine the demographic and biochemical features of childhood and juvenile thyrotoxicosis and treatment outcome. Methods: We reviewed the records of children from 22 centers in Turkey who were diagnosed with thyrotoxicosis between 2007 to 2017. Results: A total of 503 children had been diagnosed with thyrotoxicosis at the centers during the study period. Of these, 375 (74.6%) had been diagnosed with Graves' disease (GD), 75 (14.9%) with hashitoxicosis and 53 (10.5%) with other less common causes of thyrotoxicosis. The most common presenting features in children with GD or hashitoxicosis were tachycardia and/or palpitations, weight loss and excessive sweating. The cumulative remission rate was 17.6% in 370 patients with GD who had received anti-thyroid drugs (ATDs) for initial treatment. The median (range) treatment period was 22.8 (0.3-127) months. No variables predictive of achieving remission were identified. Twenty-seven received second-line treatment because of poor disease control and/or adverse events associated with ATDs. Total thyroidectomy was performed in 17 patients with no recurrence of thyrotoxicosis and all became hypothyroid. Ten patients received radioiodine and six became hypothyroid, one remained hyperthyroid and restarted ATDs and one patient achieved remission. TWo patients were lost to follow up. Conclusion: This study has demonstrated that using ATDs is the generally accepted first-line approach and there seems to be low remission rate with ATDs in pediatric GD patients in Turkey.

1 June 2020 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
ZSZeynep Siklar
Zeynep Siklar
STSerap Turan
Serap Turan
ABAbdullah Bereket
Abdullah Bereket
FBFirdevs Baş
Firdevs Baş
TGTulay Guran
Tulay Guran
MBMerih Berberoğlu
Merih Berberoğlu
Hypophosphatemic rickets (HR) is a rare renal phosphate wasting disorder commonly related to X-linked form, caused by PHEX mutations and its treatment and follow-up is challenging due to imperfect treatment options. Here we presented nationwide data on HR with initial and follow-up data on the patients. From 24 centers, 166 patients were included in the study data. Genetic analysis (n:75) showed PHEX mutation in 80% patients. The mean follow-up period of the patients was 6.7± 2.4 years. During first 3 year treatment (n:91), mild increase in phosphate , decrease in ALP and, elevation in PTH levels had been detected. The height SDS were -2.38, -2.77, -2.72, -2.47 at intitial, 1st, 2nd and 3rd year of treatment, respectively (p>0.05). In follow-up: 36% of the patients showed complete or significant improvement in leg deformities, and, these patients had similar phosphate levels at presentation with better levels in 1st and 2nd years of treatment, even the treatment doses of phosphate were similar. Furthermore, 27 patients developed nephrocalcinosis, the patients showed no difference in biochemical differences in presentation and follow-up, but 3rd year PTH was higher, however, higher treatment dose of phosphate and calcitriol has been detected in nephrocalcinosis group. HR treatment and follow-up is challenging and our results showed higher treatment doses leading nephrocalcinosis without any change in serum levels, suggesting given higher doses lead higher phoshaturia probably through the stimulation FGF23. However, higher calcitriol doses could improve bone deformities. Safer and more efficacious therapies are needed.

1 December 2021 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
PDF file
DGDamla Gökşen
Damla Gökşen
EYEdiz Yeşilkaya
Ediz Yeşilkaya
SÖSamim Özen
Samim Özen
YKYılmaz Kor
Yılmaz Kor
EEErdal Eren
Erdal Eren
ŞDŞükran Darcan
Şükran Darcan
Objective: Monogenic diabetes is a heterogeneous disease that causes functional problems in pancreatic beta cells and hyperglycemia. The aim of this study was to determine the clinical and laboratory features, the admission characteristics and distribution of monogenic form of diabetes in childhood in Turkey. Methods: Patients aged 0-18 years, who were molecularly diagnosed with monogenic diabetes, and consented to participate, were included in the study. Results: Seventy-seven (45.6%) female and 92 male cases with a mean age of 8.18 +/- 5.05 years at diagnosis were included. 52.7% of the cases were diagnosed with monogenic diabetes by random blood glucose measurement. The reason for genetic analysis in 95 (56.2%) of cases was having a family member diagnosed with diabetes under the age of 25. At the time of diagnosis, ketone was detected in urine in 16.6% of the cases. Mean hemoglobin A1c on admission, fasting blood glucose, fasting insulin, and c-peptide values were 7.3 +/- 2.1%, 184.9 +/- 128.9 mg/dL, 9.4 +/- 22.9 IU/L, 1.36 +/- 1.1 and ng/L respectively. GCK-MODY was found in 100 (59.2%), HNF1A-MODY in 31 (18.3%), and variants in ABCC8 in 6 (3.6%), KCNJ11 in 5 (3%), HNF4A in 2 (1.2%), and HNF1B in 2 (1.2%). Conclusion: Recent studies have indicated HNF1A-MODY is the most frequent of all the MODY-monogenic diabetes cases in the literature (50%), while GCK-MODY is the second most frequent (32%). In contrast to these reports, in our study, the most common form was GCK-MODY while less than 20% of cases were diagnosed with HNF1A-MODY.

1 January 2015 in Journal of Pediatric Endocrinology and Metabolism
Verified
Journal Article
Closed access
CKCelebi Kocaoglu
Celebi Kocaoglu
MBMuammer Buyukinan
Muammer Buyukinan
SESaid Sami Erdem
Said Sami Erdem
AOAhmet Ozel
Ahmet Ozel
Studies performed on mice suggest that adropin is a peptide hormone playing a role in metabolic homeostasis and prevention of obesity-associated insulin resistance. Our study was conducted to investigate the role of adropin in children with obesity or metabolic syndrome. The study group consisted of 70 patients, including 42 obese and 28 with metabolic syndrome, and 26 healthy volunteers. After anthropometric variables and blood pressure of all participants were measured, serum lipids were analyzed, liver USG and oral glucose tolerance test were performed, and HOMA-IR values were calculated. Plasma adropin levels were collectively analyzed from collected plasma samples. In patient and control groups, no difference was observed in the levels of adropin (327.7±124.7 vs. 344.6±208.5 ng/L, respectively). The adropin levels of metabolic syndrome, obesity, and control groups also showed no difference (316±142.3, 335.8±112.5, and 344.6±208.5 ng/L, respectively). While the adropin levels of patients with and without hepatic steatosis were 319.6±123.7 and 347.8±128.7 ng/L, respectively, patients with HOMA-IR values of <3.16 and ≥3.16 had levels 342.3±124.8 and 296.5±136.7 ng/L, respectively. Although statistically insignificant, our findings are considered to support the hypothesis suggesting a nexus between adropin and obesity and metabolic syndrome. Small sample size in our study may have prevented our results to reach a more significant level. So, long-term follow-up studies with large population are needed to enlighten the role of adropin in metabolic homeostasis.

1 September 2018 in Experimental and Clinical Endocrinology & Diabetes
Verified
Journal Article
Closed access
PDF file
MBMuammer Buyukinan
Muammer Buyukinan
MAMuge Atar
Muge Atar
OPOzgur Pirgon
Ozgur Pirgon
HKHuseyin Kurku
Huseyin Kurku
SES. Sami Erdem
S. Sami Erdem
IDIsa Deniz
Isa Deniz
Objective Obesity may reduce sertoli cell functions in men. The aim of the study was to investigate antimullerian hormone (AMH) and inhibin B levels (sertoli cell markers) in obese boys and their relations to cardiovascular risk factors such as insulin sensitivity index, aortic intima media thickness (aIMT) and high sensitive c-reactive protein (hsCRP). Patients, methods 121 obese and 38 healthy lean adolescents were included in the study. Serum AMH, inhibin B, gonadotropins, total testosterone, lipids, hsCRP, glucose and insulin levels were detected and analyzed. Insulin resistance was analyzed using the homeostasis model assessment (HOMA-IR). aIMT was measured by high-resolution B-mode ultrasonography. Results Serum AMH, inhibin B and total testosterone levels were lower in the obese adolescents (p = 0.01, p = 0.009 and p = 0.002, respectively). aIMT measurements (p < 0.001, 0.630.09 and 0.47 +/- 0.06 mm, respectively) and hsCRP levels (p < 0.001, 2.5 +/- 0.4 and 0.66 +/- 0.69 mg/L, respectively) were significantly increased in the obese group. Obese with IR group had decreased AMH levels (p = 0.02, 53.0 +/- 20.5 and 66.7 +/- 19.5 ng/mL, respectively) and increased triglycerides, HOMA-IR, aIMT measurements than non-IR obese group. AMH levels were correlated negatively with body mass index (r: - 0.108, p = 0.03), HOMA-IR (r: - 0.358, p = 0.003) and fasting insulin levels (r: - 0.389, p = 0.001) in obese group with IR. Conclusion We found that concentrations of both sertoli cell markers (AMH and inhibin B) were significantly lower in obese pubertal boys especially in obese with IR. Obesity and IR might be important factors for the sertoli cell impairment in pubertal boys.